MAF-specific knockout of HGF and HAS2 decreases metastatic tumor growth and strongly extends the survival of mice, suggesting that HGF and HAS2 may be therapeutic targets for desmoplastic metastatic cancers [37]. This evidence concerns the gene HGF and metastatic malignant neoplasm.